Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:12 Issue:1 Number:1 ISSN#:2563-5476
RCT
ACE Report #13267
Ace Report Cover General Orthopaedics

Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19


How to Cite

OrthoEvidence. Xuebijing Injection Reduces Inflammatory Response and Disease Severity in Patients with COVID-19. ACE Report. 2021;12(1):1. Available from: https://myorthoevidene.com/AceReport/Report/13267

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial

Eur J Integr Med. 2021 Feb; 42: 101305.

Contributing Authors: Z Luo W Chen M Xiang H Wang W Xiao C Xu Y Li J Min Q Tu

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Sixty patients with severe COVID-19 were randomized to receive routine care plus intravenous Xuebijing injection (n=30) or routine care alone (n=30) for the suppression of inflammatory response and management of symptoms. The primary outcome of interest was peripheral blood lymphocyte and interleukin (IL)-6 levels which were measured at 1, 7 and 14 days follow-up. Secondary outcomes of interest in...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE